Trial watch: Ipilimumab success in melanoma provides boost for cancer immunotherapy

摘要

Phase III trial results for ipilimumab, an immunomodulatory monoclonal antibody that targets cytotoxic T-lymphocyte antigen 4 (CTLA4), showed that it increased survival by 3.7 months in patients with advanced melanoma (N.Engl.J.Med. 14 Jun 2010; doi:10.1056/ NEJMoal003466). "These findings are appropriately receiving a lot of attention, because this is the first randomized Phase III trial demonstration of a significant survival impact for a treatment for patients with metastatic melanoma," says Vernon K. Sondak, M.D., Chair of the Department of Cutaneous Oncology, Moffitt Cancer Center, Florida, USA.